中大脳動脈閉塞のマウスモデル

Executive Industry Relevance

The mouse model of middle cerebral artery occlusion (MCAO) provides a robust, reproducible platform for evaluating ischemic stroke mechanisms and potential therapeutic interventions in preclinical research. This model enables quantitative assessment of infarct size and supports translational continuity from early discovery through preclinical validation. Its widespread adoption in neuroscience R&D reflects its value for mechanistic de-risking and predictive confidence in cerebrovascular target validation.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of cerebrovascular injury pathways relevant to ischemic stroke.
• Supports functional validation of neuroprotective targets in a disease-relevant system.
• Facilitates mechanistic de-risking by modeling both permanent and transient ischemic events.
• Provides quantitative endpoints for hypothesis-driven target triage.

Screening & Assay Development

• Establishes a validated in vivo system for evaluating candidate compounds' efficacy in reducing infarct size.
• Standardizes assessment through TTC staining, enabling reproducible and quantitative readouts.
• Prepares a scalable workflow for screening neuroprotective agents in a controlled ischemic context.
• Enables reliable comparison of intervention effects across experimental cohorts.

Translational & Preclinical Research

• Aligns with human stroke pathology by targeting the MCA territory, enhancing translational relevance.
• Supports biomarker discovery and validation through quantifiable infarct measurements.
• Facilitates risk-adjusted advancement of neuroprotective strategies into later-stage studies.
• Provides continuity from mechanistic discovery to preclinical efficacy evaluation.

Pipeline & Workflow Integration

This MCAO model bridges early discovery, lead identification, and preclinical validation for cerebrovascular targets and interventions.

• Discovery Biology: Enables hypothesis testing and pathway clarification in ischemic stroke models.
• Screening: Delivers reproducible, quantitative infarct size measurements for compound evaluation.
• Analytics: Provides standardized TTC staining outputs for cross-condition statistical analysis.
• Translational Research: Maintains disease relevance and supports biomarker alignment for preclinical studies.
• Enterprise Reuse: Functions as a reusable platform for diverse neurovascular research and therapeutic screening.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in stroke research.
• Operational Value: Promotes standardization, reproducibility, and scalability in preclinical workflows.
• Strategic Value: Informs go/no-go decisions and enhances capital efficiency by providing robust efficacy data.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of neuroprotective candidates.

Implementation Considerations

• Requires surgical expertise in vascular occlusion and animal handling.
• Needs access to precise instrumentation for suture preparation and brain slicing.
• Demands cross-team standardization of TTC staining and infarct quantification protocols.
• Adaptable to both permanent and transient occlusion models for broader research utility.
• Potential limitations include variability in infarct size and technical complexity of the procedure.

Biopharma FAQs